Statins, or HMG-CoA reductase inhibitors, have gained prominence among pharmacological interventions due to their ability to lower low-density lipoprotein (LDL) cholesterol, a primary contributor to atherosclerosis and subsequent CV events [2,3]. This evidence concerns the gene HMGCR and atherosclerosis.